Affimed Nv Share Price

NASDAQ: AFMD

$0.18

-0.10

(-34.48%)

Live

as on May 20, 2025 at 1:28 am IST

$₹

The stock has been delisted from the stock exchange on 16 May 2025

Affimed Nv Stock Performance

as on May 20, 2025 at 1:28 am IST

$0.18
Day's Price Range
$0.18
$0.18
52 Week's Low
52 Week's High
$0.07
52-Week Price Range
$4.2
$0.18
61.06%
Downside
2232.00%
Upside

Affimed Nv share price movements today

Previous Close: $0.28
Open: $0.18
Volume: 100.0
Day's Low - High: $0.18 - $0.18
52 Week Low - High: $0.07 - $4.2

Affimed Nv Historical Returns

1 Month Return: 0 %
3 Month Return: 0 %
1 Year Return: 0 %
3 Year Return: 0 %
5 Year Return: 0 %

Affimed Nv Stock Fundamentals & Key Indicators

Check Affimed Nv market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

EPS (TTM)

Dividend Yield

0.00%

PE Ratio (TTM)

P/B Ratio

PEG Ratio

Return On Equity TTM

0.00%

Affimed Nv stock Key Stats

Compare market cap, revenue, PE, and other key metrics of Affimed Nv with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Affimed Nv	BUY	$-	NA	NA	0.00%

Analyst Recommendation on Affimed Nv Stock

Based on 14 analysts

BUY

85.71%

Buy

14.29%

Hold

0.00%

Sell

Based on 14 analysts, 85.71% of analysts recommend a 'BUY' rating for Affimed Nv. Average target price of $0.39

Affimed Nv Share Price Target

Get share price movements and forecasts by analysts on Affimed Nv.

What analysts predicted

53.85%UPSIDE

Target Price

$0.39

Current Price

$0.18

Analyzed by

14 Analysts

Target

$0.39

Affimed Nv target price $0.39, a slight upside of 53.85% compared to current price of $0.18. According to 14 analysts rating.

Affimed Nv Quarterly Profit & Loss

All numbers in Millions USD

	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Total Revenue	7	14	11	4	1	2	0	0	0	0
Gross Profit	7	14	11	4	1	2	0	0	0	0
Operating Income	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-	-
Depreciation	-	-	-	-	-	-	-	-	-	-
Income Before Tax	-	-	-	-	-	-	-	-	-	-
Income Tax Expense	-	-	-	-	-	-	-	-	-	-
Net Income	-18	-13	-38	-34	-31	-25	-22	-19	-15	-15
Net Profit Margin	-234.98%	-92.50%	-329.18%	-709.16%	-2114.75%	-1241.34%	-4892.25%	-12370.97%	-10033.12%	-9767.10%

Affimed Nv Annual Profit & Loss

All numbers in Millions USD

	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023
Total Revenue	4	8	6	2	26	23	34	45	43	9
Gross Profit	4	8	6	2	26	23	34	45	43	9
Operating Income	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-	-
Depreciation	-	-	-	-	-	-	-	-	-	-
Income Before Tax	-	-	-	-	-	-	-	-	-	-
Income Tax Expense	-	-	-	-	-	-	-	-	-	-
Net Income	0	-22	-33	-35	-22	-35	-50	-65	-91	-115
Net Profit Margin	-7.66%	-267.64%	-510.23%	-1503.63%	-82.06%	-151.30%	-145.86%	-142.50%	-207.98%	-1280.22%

Global Institutional Holdings in Affimed Nv

Funds	Holdings
683 Capital Management LLC	3.99%
NEA Management Company, LLC	2.7%
Point72 Asset Management, L.P.	2.09%
Northern Trust Corp	1.12%
TANG CAPITAL MANAGEMENT LLC	0.9%

See all

About Affimed Nv

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The Company is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.

Organisation	Affimed Nv
E-voting on shares	Click here to vote

FAQs

What is Affimed Nv share price today?

Affimed Nv share price today is $0.18 as on May 20, 2025 at 1:28 am IST. Affimed Nv share today touched a day high of $0.18 and a low of $0.18.

What is the 52 week high and 52 week low for Affimed Nv share?

Affimed Nv share touched a 52 week high of $4.2 on September 17, 2024 and a 52 week low of $0.07 on May 15, 2025. Affimed Nv stock price today i.e. May 20, 2025 at 1:28 am IST is trending at $0.18,which is 95.71% down from its 52 week high and 156.78% up from its 52 week low.

How to invest in Affimed Nv Stock (AFMD) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Affimed Nv on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Affimed Nv Shares that will get you 8.3333 shares as per Affimed Nv share price of $0.18 per share as on May 20, 2025 at 1:28 am IST.

What is the minimum amount required to buy Affimed Nv Stock (AFMD) from India?

Indian investors can start investing in Affimed Nv (AFMD) shares with as little as ₹88.115 or $1 (as of September 4, 2025 at 9:01 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹881.15 in Affimed Nv stock (as per the Rupee-Dollar exchange rate as on September 4, 2025 at 9:01 pm IST). Based on Affimed Nv share’s latest price of $0.18 as on May 20, 2025 at 1:28 am IST, you will get 55.5556 shares of Affimed Nv. Learn more about fractional shares .